<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02980250</url>
  </required_header>
  <id_info>
    <org_study_id>NFEC-2015-131</org_study_id>
    <nct_id>NCT02980250</nct_id>
  </id_info>
  <brief_title>Multi-Center Study of Different Doses Domperidone in Feeding Intolerance</brief_title>
  <acronym>MCSDDDFI</acronym>
  <official_title>A Clinical Multi-Center Study of Efficacy Analysis in Different Doses of Domperidone in Feeding Intolerance of Premature Infant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Guangdong Provincial Maternal and Child Health Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shen-Zhen City Maternity and Child Healthcare Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maternal and Child Health Hospital of Foshan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangzhou Panyu Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nanfang Hospital of Southern Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical multi-center study is to determine whether different doses of
      domperidone are effective in the treatment of feeding intolerance in premature infant
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      the premature infant have been divided into four group.The first group take the 0.2mg/kg/tds
      domperidone as treatment ,while the other group take the 0.4mg/kg/tds
      domperidone,0.6mg/kg/tds domperidone and the placebo respectively .

      An objective index has been decided to evaluate the severity of feeding intolerance in the
      premature infant. 3kg/kg 5% glucose will be injected into the gastric tube .The residual
      glucose will be drawed out from the gastric tube. The residual percentage is the main result
      of the study.

      The main result will be compared by the secondary result to help to explain the accuracy. The
      secondary result is the percentage of residual milk drawed out from the gastric tube from how
      many milk the infant take 3 hours ago.

      Any adverse effect will be recorded and analysed to figure out whether is associate with the
      domperidone.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Actual">June 2017</completion_date>
  <primary_completion_date type="Actual">May 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the residual glucose percentage</measure>
    <time_frame>7 days</time_frame>
    <description>3kg/kg 5% glucose will be injected into the gastric tube .The residual glucose will be drawed out from the gastric tube after 30 min</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the percentage of residual milk</measure>
    <time_frame>7 days</time_frame>
    <description>the percentage of residual milk drawed out from the gastric tube from how many milk the infant take 3 hours ago.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>1 month</time_frame>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">118</enrollment>
  <condition>Feeding Intolerance</condition>
  <condition>Premature Birth</condition>
  <condition>Domperidone Overdose</condition>
  <condition>Gastric Retention</condition>
  <arm_group>
    <arm_group_label>low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The premature infant in this group will be feed with 0.2mg/kg/tds domperidone suspension(motilium;100ml)for 7 days and will be tested the residual percentage everyday.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>normal dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The premature infant in this group will be feed with 0.4mg/kg/tds domperidone suspension(motilium;100ml)for 7 days and will be tested the residual percentage everyday.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>over dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The premature infant in this group will be feed with 0.6mg/kg/tds domperidone suspension(motilium;100ml)for 7 days and will be tested the residual percentage everyday.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The premature infant in this group will be feed with some vitamin which will dilute into the 5% glucose and have the same appearance and taste with the experimental team for 7 days and will be tested the residual percentage everyday.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low dose</intervention_name>
    <description>0.2mg group-The premature infant will be fed with 0.2mg/kg/tds domperidone and will be tested the residual glucose everyday in a 7-days period.</description>
    <arm_group_label>low dose</arm_group_label>
    <other_name>Domperidone Suspension(Motilium), B12200018238</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>normal dose</intervention_name>
    <description>0.4mg group-The premature infant will be fed with 0.4mg/kg/tds domperidone and will be tested the residual glucose everyday in a 7-days period.</description>
    <arm_group_label>normal dose</arm_group_label>
    <other_name>Domperidone Suspension(Motilium), B12200018238</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>over dose</intervention_name>
    <description>0.6mg group-The premature infant will be fed with 0.6mg/kg/tds domperidone and will be tested the residual glucose everyday in a 7-days period.</description>
    <arm_group_label>over dose</arm_group_label>
    <other_name>Domperidone Suspension(Motilium), B12200018238</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucose</intervention_name>
    <description>Glucose group-The premature infant will be fed with glucose and will be tested the residual glucose everyday in a 7-days period.</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>5% Glucose</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  the residual milk and glucose over 55%

          -  abdominal distention or vomiting;

          -  Reduce,delay or disruption of enteral feeding

        Exclusion Criteria:

          -  Four weeks before the start of this study had participated in other clinical trials

          -  pulmonary hypertension;

          -  Infants with necrotizing enterocolitis

          -  Gastrointestinal tract malformation, congenital heart disease

          -  Pre-existing QT extend/between long QT syndrome;

          -  ascites

          -  Have been used or will use drugs suppress CYP3A4

          -  Other risk factors for prolong the QT
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Weeks</minimum_age>
    <maximum_age>35 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>WeiMing Huang, professor</last_name>
    <role>Study Chair</role>
    <affiliation>Nanfang Hosiptal</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nanfang Hospital of Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2016</study_first_submitted>
  <study_first_submitted_qc>December 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2016</study_first_posted>
  <last_update_submitted>September 13, 2017</last_update_submitted>
  <last_update_submitted_qc>September 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nanfang Hospital of Southern Medical University</investigator_affiliation>
    <investigator_full_name>Weimin Huang</investigator_full_name>
    <investigator_title>The director of the neonatology department</investigator_title>
  </responsible_party>
  <keyword>feeding intolerance</keyword>
  <keyword>premature infant</keyword>
  <keyword>domperidone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Domperidone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

